Background: Chronic pain is a common problem in children, and the number of medications available for treating such pain is limited. Ketamine is an NMDA receptor antagonist that has been shown in some adults to improve control of pain by decreasing central sensitization. Although there are anecdotal reports and small case series of oral ketamine for children with chronic pain, there are no data on appropriate dosing, safety, and efficacy in this setting. Objective: To estimate the maximum tolerated oral dose of ketamine for children with chronic pain. Methods: Children and adolescents aged 8-22 years old with chronic pain from neuropathy and other illnesses were eligible to enroll in this Phase 1 study. Cohorts of 3 subjects were treated according to the modified continual reassessment method of dose finding. Each subject was given ketamine orally, three times daily for 12 days, followed by 2 days of a ketamine taper. The starting dose was 0.25 mg/kg/dose. Toxicity was assessed and dose-limiting toxicity determined using the NCI Common Toxicity Criteria for Adverse Events version 4.0. Secondary outcomes included pain response (using the 1-10 numerical rating scale for pain) at 0, 14, and 42 days; neurocognitive function at baseline, 2 weeks, and 14 weeks; and steady-state plasma concentrations of ketamine and norketamine measured for pharmacokinetic analysis. Results: To date, 7 subjects have been enrolled: 3 were treated at 0.25 mg/kg/dose, 3 at 0.50 mg/kg/dose, and 1 at the 1 mg/kg/dose level. Thus far there have been no dose
Neurodermatologic conditions are various disorders affecting the nervous system and the cutaneous (skin) layers. In this study, we included the medically unclassified condition termed morgellons which generally, is labeled as delusional parasitoses and is characterized from this study as Neurotoxin Spongy Fibrous Syndrome (NTSFS). This characterization reflects the biology, pathology and clinical features of the disease. Some of the observed presentations, signs & symptoms include but not limited to crawling, burning, tingling and itching sensations; skin discolorations, rashes, blisters, boils, and ulcers. Also reported are neuromuscular pain syndrome, tinnitus, pest biting, and emotional disturbances. Harmful algal blooms, fungal colonizations, poor wound healing and spongy fiber deposits on the skin were observed. We have designed reversal reactive release (eR3) that was demonstrated in-vivo to cause interstitial fluid reversal osmosis, a process needed by germ barrier activators for purification of interstitial fluid that in turn stimulates the elimination of bacteria, viruses, foreign bodies, abnormal cells, trapped toxifying gas & free radicals from the system through the cutaneous exfoliations. Method: Double blinded study of 80 candidates were conducted under four groups of 20 candidates each namely:-Control, Mongellons Pest, Wound Burn & Hygienic. With specific instructions to apply the solution 1-2 times daily with or without bath, as follows:-1 hr before bath, with bath, 1 hr after bath & the control (made up of other group representatives), without bath for 90 days. All candidates were matched accordingly & the standard human research ethics & protocols were adhered to according to the sfn guidelines. Result: Those on 2x daily with bath showed significant improvement more than those with 2x daily without bath, & those on 1x daily with bath showed some improvement than the control. Generally, those with Neurotoxin Spongy Fibrous Syndrome (Morgellons pest candidates) showed significant improvements, an observation that debunks the myth of its assumed incurability. Conclusion: Although this study is still ongoing, it shows that personal hygiene is a contributive factor to neurotoxic dermatological disorders and infections. It also shows that Clinoxide as a cleanser, is an effective agent in germ / infection control, wound healing, sunburn barrier, topical analgesia, systemic detoxification, pest bites morgellon syndrome control through its action of reversal reactive release of oxygen into the tissue & Co2 off the tissues, thus activates the rebathing of the cells by electrolyzing the interstitial fluid flow to the heart that reinforces the immunity response of lymphocytes and macrophages to engulf the invading bacteria, virus, or foreign bodies, etc.
Effect of beta-estradiol on myelination of neurons by oligodendrocytes in coculture: a new long term in vitro model of central myelination Callizot Noelle, PhD, Combes Maud, MSc, Einius Sylvain, Steinschneider Remy, PhD. Neuron Experts SAS Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS), the cause of MS is not clear, but its pathology consists of immune infiltration into the CNS, inflammation, demyelination and finally axonal degeneration. The development of therapies to promote remyelination in MS is a key research aim, to both aid restoration of electrical impulse conduction in nerves and provide neuroprotection, reducing disability in patients. Currently, most researchers use in vitro models of developmental myelination and in vivo models of remyelination. In vitro systems culturing oligodendrocyte precursor cells (OPCs) with CNS or peripheral nervous system neurons are relatively simple, not relevant to physiology and not adapted to high-throughput screening, and testing a remyelination therapy in the many and various in vivo models of MS is expensive in terms of time, animals and money. Thus, a relevant and robust system mimicking the physiological aspect of the central myelination is needed to find new potential treatments. Myelination in the CNS involves sequential developmental processes in which OPCs migrate, proliferate, and differentiate into newly formed oligodendrocytes, after which those oligodendrocytes (OL) selected by target-dependent survival mechanisms wrap myelin membrane around the axons to form the sheath. Each oligodendrocyte can myelinate many axons, with the number of wraps proportional to the axon diameter and regulated tightly by reciprocal signaling between oligodendrocyte and axons. To be relevant, a model of CNS myelination has to reproduce chronically these different steps of the process. Here, we developed a new and reproducible in vitro myelination model based on primary cocultures of central neurons and OL culturing in 96-well plate and then adapted to high throughput screening. We also have developed an automated system of quantifying myelination, to enable the use of this model as a fast and objective screen. The total forebrains were removed from 17-day-old Wistar fetuses, dissociated mechanically, cells were plated (30000 / well) on a laminin and poly-Llysine-coated in 96-well plates. The cocultures were maintained in neurobasal medium in presence of recombinant platelet-derived growth factor AA (PDGF-AA, 10 ng/ml). We carefully characterized the model through migration of OPC to OL differentiation from early stage (day 3 post culture) up to day 25 (allowing kinetic studies of myelin formation both at a molecular and cellular level). Specific markers of myelin formation were used; the differentiation of OPCs (NG2 and O4) into the mature OL (MAG and MBP) was observed. Kinetics of myelin formation was assessed showing the compact myelin formation (MBP staining) around neuron axons. Immature and mature neuron integrity was studied using respectively microtubuleassociated-protein 2 (MAP-2) and neurofilament (NF) staining. On this well characterized system mimicking in vitro the physiological process of in vivo myelination, the effect of b-estradiol in chronic treatment was studied. We showed that treatments of coculture model by b-estradiol (50 nM) were able to increase the proliferation of OPCs (as well as the formation of myelin (MAG) and its maturation (MBP). A significant increase of number of myelinated OL was observed. These results suggest that b-estradiol could be a possible appropriate therapeutic strategy to interfere with the progress of the still incurable central demyelinating disorders as MS. 
Background:
In an effort to reduce study start-up time and accelerate data sharing in neuroscience research, the NINDS embarked on the CDE Project in 2006. The Project commenced with the development of the General CDEs, which are a collection of variables commonly captured across therapeutic areas, such as demographic information. The General CDEs are evaluated periodically and are currently available on the NINDS CDE Project Web site (www. commondataelements.ninds.nih.gov) for public use. Methodology: The General CDEs were initially developed by reviewing the literature, case report forms (CRFs) from large NINDS-funded studies, other clinical data standards, and regulatory requirements. Since the initial development, the General CDEs have been modified in order to harmonize with other standardization efforts and maximize utility; Version 4.0 of the General CDEs was released in February of 2010. Subsequently, over the past three years, diseasespecific CDEs have been developed by Working Groups of research experts to support the General CDEs and make a comprehensive suite of study documents/data collection tools. Both the General and disease-specific CDE recommendations are presented in the standardized CDE Project documentation, which consists of two formats: CRF Modules and Data Dictionaries. In addition to the General CDEs, these tools are also available for the disease area CDEs. Additional disease areas are under development and will be added to the Web site tools once released by the Working Groups. Conclusions: The NINDS recognizes the best way to ensure the CDEs remain a useful set of tools is through periodic review, to account for the changing research landscape as well as scientific advancements. To achieve this goal, the NINDS has assembled a CDE Steering Committee comprised of 30 researchers representing a variety of domestic and international institutions, to provide recommendations as to how the General CDEs should be updated in order to maintain currency. The disease-specific CDEs are reviewed on a regular basis by Oversight Committees that focus on incorporating changes to the existing recommendations. Additionally, the General and disease-specific CDE are revised based on feedback received from the community, as submitted through the NINDS CDE Project Web site. The Institute strongly encourages researchers to submit feedback both about the utility of the Web site and the CDEs. Results: The development of antidepressant in pediatric MDD has mainly been conducted in the US, with a vast majority of studies only performed in the US. Compared to the US, the EU experience in pediatric research is less extensive. Three years after the implementation of the European pediatric regulation, a large number of PIPs have been agreed upon and should be implemented in the coming years. So far, the proportion of pediatric trials as a percentage of all clinical trials has however moderately increased (from 8.2 to 9.4 % of all trials). But, because of the US and EU regulatory requirements and ongoing pediatric initiatives in Australia, Canada and Japan, the number of pediatric clinical trials is anticipated to increase. Therefore access to appropriate study patient population will only be possible through worldwide recruitment. Conclusions: Because of pediatric regulatory requirements, the number of pediatric clinical trials is anticipated to increase. Limitation in appropriate study patient population necessitates recruitment of patients globally. Ultimately well-conducted research triggered by both US and EU pediatric regulations may bring pediatric populations access to new medications not only in US and EU but indeed globally.
Inhibition of Connexin 43 and p38/MAPK pathway contribute to the protective effect of Gingko biloba Extract's (EGb761) in ischemic rat
Yu Yongjuan, PhD, Mou Fangfang, Zhang Zean, University of Shanghai Traditional Chinese Medicine EGb761 is a standard plant extract from Ginkgo Biloba which has been used in ischemic diseases for hundred years. Previous studies have confirmed the neuroprotective effects of EGb761 under ischemia conditions. The present study aimed to explore the roles of Cx43 and p38/MAPK signal pathway in EGb761 mediated neuroprotection in vitro and in vivo. Rats were delivered with EGb761 (50 mg/kg, 100 mg/kg) orally 10 days before 60 min ischemia/24 h reperfusion. And rat cortical primary cells were transfected with Cx43-shRNA and treated with EGb761 (200ug/ml) for 12 h.Using TTC staining, immunohistochemisty and western blot techniques, we observed the infarct area and cell apoptosis number in rat brain, and compared the level of Cx43/p-Cx43 and p38/p-p38 protein in rat brain tissues and cortical primary neuron cells with or without Cx43 knockout. Our study displayed that pretreatment with EGb761 reduced the neurological deficits score of ischemic rat, significantly inhibited the caspase-9 expression and neuronal apoptosis in penumbra area. The phosphorylation of p38/ MAPK and Cx43 in the cortical brain decreased after treated with EGb761. In addition, the p-p38 level of primary cortical cells increased after Cx43 was knockout. In conclusion, EGb761 effectively reduced the infarct area and neuronal apoptosis in ischemic brain of rats. The neuroprotective effects of EGb761 toward ischemia-induced injury may be partially determined by Cx43 and p38/MAPK signaling pathway. Alpha5 subunit-containing GABAA receptors (GABAARs) and alpha7 neuronal nicotinic-acetylcholine receptors (nAChRs) are members of the Cys-loop family of ligand-gated ion channels (LGICs) that each mediate differential cognitive processes in the hippocampus. Both receptors are pharmaceutical targets for the treatment of Alzheimers disease, cognitive deficits in schizophrenia, and ADHD. alpha5 GABAARs are primarily restricted to the hippocampus in distribution and tonically inhibit CA1/CA3 pyramidal cells. Inverse agonists at alpha5 GABAARs have demonstrated cognitive enhancement in animal and human studies. Conversely, alpha7 nAChR stimulation has also demonstrated cognitive enhancement via inhibition of GABAergic interneuron activity and promotion of glutamate release in the CA1. We report herein the development of a dual allosteric modulator, AVL-8168, acting positively on alpha7 nAChRs and negatively on alpha5 GABAARs in its modulatory effects. Interestingly, not only does AVL-8168 produce synergistic enhancement of excitatory post-synaptic currents (EPSC) in the CA1 but also long-term potentiation (LTP) in response to mossy fiber stimulation. Selective antagonists for either receptor block sustained EPSC potentiation produced by AVL-8168. In vivo, AVL-8168 enhanced performance in the radial arm maze and facilitated attention in the five choice serial reaction time trial (5-CSRTT), both effects again blocked by selective antagonism of alpha7 nAChRs and alpha5 GABAARs. These observations and the development of AVL-8168 highlight the therapeutic utility of dual action compounds in diseases of cognitive impairment.
Nonsedating Anxiolytic and Analgesic Properties of Proprietary S-Etifoxine
Jason Bermak, MD PhD and David Putman, PhD, Anvyl Etifoxine (Stresam®) is a generic, racemic, anxiolytic medication, broadly prescribed in 20 countries outside the United States. Its popularity of use stems from the consistent finding that etifoxine produces anti-anxiety effects equivalent to that of benzodiazepines (BZs) without the abuse potential, sedation, cognitive impairment or rebound anxiety typically observed from BZs. Etifoxine has been shown to exhibit anxiolytic efficacy through GABAA receptor allosteric modulation. Importantly, etifoxine has also been also been shown to possess highly efficacious analgesic and nerve-regenerative effects via peripheral benzodiazepine receptor (i.e. TSPO) activation and neurosteroid biosynthesis. We report, herein, the discovery of the proprietary S-isomer of etifoxine that is responsible for the potent anxiolytic and analgesic effects of racemic etifoxine and, significantly, lacks sedative and ataxic effects. In separate studies, we have shown that beta-2 subunit selective potentiation of GABAA receptors is responsible for non-sedating anxiolysis. As expected, S-etifoxine demonstrates highly selective allosteric potentiation of beta-2, but not beta-1, containing GABAA receptors. S-etifoxine represents an unusual opportunity for the U.S. development of a novel and potent analgesic/anxiolytic that has already proven itself safe and efficacious in humans for over 30 years as part of a racemic drug in non-U.S. markets. An economical, commercial scale enantioselective synthetic pathway has been developed for this purpose.
Antagonism of LINGO-1: A Novel Approach to Enhance Remyelination in Multiple Sclerosis
Diego Cadavid, MD, Biogen Idec Multiple sclerosis (MS) is a chronic disabling neurological disease characterized by widespread injury to the white and gray matter of the central nervous system (CNS). Currently approved MS therapies are immunomodulatory and reduce inflammation without promoting CNS repair. There is a high unmet need for new MS therapeutics that promote remyelination and provide neuroaxonal protection and repair. Some evidence suggests that the lack of remyelination in MS lesions results from an inability of existing oligodendrocyte precursor cells (OPCs) to differentiate into mature myelinforming oligodendrocytes. Biogen Idec has identified LINGO-1 as a potent negative regulator of OPC differentiation and myelination. LINGO-1 is selectively expressed in brain and spinal cord and not in peripheral tissues. LINGO-1 antagonists promote OPC differentiation and axonal myelination in vitro, improve remyelination in rodent models of inflammatory (EAE), and chemical (Cuprizone and LPC) induced demyelination, and improve neuroaxonal survival following acute transection in the optic nerve and spinal cord. Biogen Idec is exploring the therapeutic potential of BIIB033, a fully human monoclonal antibody that is a selective and potent antagonist of LINGO-1 function with high affinity for human and rodent LINGO-1. Systemic administration of BIIB033 in rat LPC and EAE disease models revealed dose-dependent remyelination. BIIB033 levels in spinal cord that promoted remyelination correlated well with affinity measurements for its binding to LINGO-1. The safety and tolerability as well as CSF to plasma ratios of BIIB033 have been evaluated in phase 1 studies in healthy adult volunteers and in relapsing remitting and secondary progressive MS patients. The results of these phase 1 studies will be reported at the upcoming AAN annual meeting in the spring of 2012. Reducing alpha-synuclein accumulation is a main target for the development of neuroprotective therapies for Parkinson's disease (PD) and other synucleinopathies. A high rate of mutations in the lysosomal hydrolase glucocerebrosidase (GCase) that lead to dysfunction of GCase is found in patients with PD and, experimentally, GCase dysfunction promotes alphasynuclein accumulation. The pharmacological chaperone afegostat-tartrate (AT2101) increases the stability, trafficking, and activity of GCase in vivo. We have administered AT2101 orally for 4 months to mice that overexpress human wild-type alpha-synuclein (Thy1-aSyn mice) and measured motor function on the challenging beam and pole test, olfaction, microglial morphology, alpha-synuclein levels by fluorescence immunohistochemistry and the size and number of proteinase-K resistant alpha-synuclein aggregates in tissue sections. We report that AT2101 improves motor and non-motor behavioral deficits, and reduced microglial activation, alpha-synuclein levels in nigral dopaminergic neurons, and the number of small aggregates while increasing the number of large aggregates in the substantia nigra. The data suggest that pharmacological chaperones that target GCase may provide protection in PD and other synucleinopathies. As such, AT2101 has been administered safely to healthy subjects in phase 1 and to Gaucher patients in phase 2. Additionally, analogs of AT2101 with improved pharmacokinetic and pharmacodynamic properties such as increased penetration of the blood brain barrier, have been identified, and for which preclinical studies are underway for at least one of these compounds.
MANF: A Bifunctional Protein with Multiple Therapeutic Indications
John Commissiong, PhD, Amarantus Therapeutics, Inc.
MANF is neuroprotective and is up regulated in the unfolded protein response. It is a novel 18 kDa, astrocyte-derived, secreted protein, with well defined N-and C-terminal domains separated by a linker region. It is one of the first potential drug candidates to result from our increased understanding of astrocyte-neuron biology and it has multiple potential CNS therapeutic indications. In 2010, the sixteen NIH Institutes, Centers, and Offices that comprise the NIH Blueprint for Neuroscience Research announced a Grand Challenge for Neurotherapeutics to address the paucity of effective treatments for disorders of the nervous system. As one of the Grand Challenge initiatives, the NIH established the Blueprint Neurotherapeutics Network (BPN), a virtual pharmanetwork of contract service providers and consultants with extensive industry experience. This network is designed to advance projects from early medicinal chemistry through phase I clinical testing and facilitate industry partnerships for their subsequent development. The NIH has solicited applications for U01 cooperative agreement awards from investigators with small molecule compounds that could be developed into clinical candidates within this network. Awards provide: 1) funding to support biological testing of compounds and 2) access to technical, infrastructure, and advisory resources to enable investigators to translate promising small molecule compounds into drug candidates that have completed phase I clinical trials. The program is structured to allow award recipients to retain ownership of intellectual property for compounds developed within the BPN. To date, seven projects have been accepted into the BPN. The BPN has the capacity to initiate up to 20 projects, total, with the expectation that some projects may end early due to lack of milestone achievement. A list of projects currently in the BPN, consultants, and contract service providers can be viewed at http://neuroscienceblueprint. nih.gov/bpdrugs/bpn.htm. The final solicitation will be released in the spring of 2012 and will have a receipt date in June 2012. Applicants must have: 1) at least one small molecule compound with strong evidence of biological activity relevant to the intended indication as a starting point for medicinal chemistry optimization; 2) a robust, moderate throughput assay of biological activity suitable for testing 20-40 compounds in a 1-2 week iterative chemical optimization cycle; 3) secondary bioassays and models sufficient to evaluate the potential of a drug candidate for the intended indication.
An Alpha-7 Nicotinic Partial Agonist, EVP-5124, Produces Positive Effects on Cognition, Clinical Function, and Negative Symptoms in Patients with Chronic Schizophrenia on Stable Antipsychotic Therapy

Dana C. Hilt, MD, Envivo Pharmaceuticals
Background: Patients with schizophrenia have residual cognitive deficits, even after treatment with available antipsychotic therapies (CIAS). Currently, several procognitive therapies are under development for this condition. EVP-6124 is a potent, selective a-7 partial agonist. A Phase 2b study in schizophrenic patients (n0319) receiving stable chronic atypical antipsychotic therapy has been completed. The safety and efficacy of two different doses of EVP-6124 (0.3 and 1.0 mg/d) vs placebo over 3 months was studied. Efficacy was measured by the CogState OCI and the MCCB. Function was assessed by the SCoRS and PANSS (positive and negative). Results: Patients were treated with either placebo (n0106), 0.3 mg/d (n0107), or 1 mg/d (n0107) for 84 days. Participants from 18-55 years of age from the US (54 %) and four other countries (46 %) were enrolled. The drug was well tolerated. The effect on the OCI was statistically significant among the treatment groups (p 0 0.05) compared to placebo. There was a significant (p0 0.009, ES00.34) effect on the OCI in the 0.3 mg group. This observation was supported by a trend in the MCCB (performed only in a subset of US patients: n0166). The mean change from baseline in the SCoRS(I) rating over all visits between the 1 mg and placebo group was significant (p00.011, ES00.36). Improvement was also seen in the PANSS Negative subscale (p00.028, ES00.33) at the end of the study vs baseline. The beneficial effects of EVP-6124 will be further investigated in larger confirmatory studies. The conduct of this study (EVP-6124-009) was supported by Envivo Pharmaceuticals, Watertown, MA 02472.
Coversin, a Complement Inhibitor, Ready for Phase 2 Evaluation for Myasthenia Gravis and Beyond
Henry J. Kaminski, MD, Department of Neurology, George Washington University; Wynne Weston-Davies, Varleigh Immuno Pharmaceuticals, Ltd; Michael Benatar, MD, PhD, University of Miami; Linda Kusner, PhD, George Washington University Myasthenia gravis (MG) is the prototypic antibodymediated autoimmune disease in which the antigenic target is typically the nicotinic acetylcholine receptor clustered on the post-synaptic membrane at the neuromuscular junction. Complement mediated injury of the neuromuscular junction is considered a primary disease mechanism in human myasthenia gravis and animal models of experimentally acquired myasthenia gravis (EAMG). Coversin is a 18.5 kD recombinantly produced protein derived from tick saliva. Standardized disease severity assessment, serum complement hemolytic activity, serum cytotoxicity, acetylcholine receptor (AChR) antibody concentration, IgG subclassification, and C9 deposition at neuromuscular junction were used to assess the effect of complement inhibition on EAMG induced by administration of AChR antibody or immunization with purified AChR. We have found that administration of rEV576 in passive transfer EAMG model limited disease severity as evidenced by 100 % survival rate and a low disease severity score. In active EAMG, rats with severe and mild EAMG were protected from worsening of disease and had limited weight loss. Serum complement activity (CH50) in severe and mild EAMG was reduced to undetectable levels during treatment, and C9 deposition at the neuromuscular junction was reduced. Coversin has undergone extensive rodent and monkey toxicity assessment and no adverse effects detected. Phase I testing is underway and a Phase II evaluation is under development. The goals of the Phase II will be (a) to evaluate intermediate term safety/tolerability, (b) determine optimal dosing, and (c) to acquire preliminary efficacy data for outcome assessment. Ongoing preclinical work has demonstrated that Coversin can be modified with agents that target the neuromuscular junction without producing weakness or systemic complement inhibition. These studies offer the future development of second generationcomplement inhibitors with improved efficacy and fewer adverse effects. Based upon the clinical findings, we tested the efficacy of a selective GCPII inhibitor, known to increase brain NAAG levels, in cognition tests in the rodent experimental autoimmune encephalomyelitis (EAE) model of MS. We show that while administration of a GCPII inhibitor did not affect physical disabilities in the animals, it increased brain NAAG levels and augmented learning and memory capabilities. This beneficial effect is likely caused by decreased synaptic glutamate concentration and/or increased NAAG levels, which is an mGluR3 agonist. The development of pre-clinical models to test novel therapeutics for cognitive impairment in CNS autoimmune and neurodegenerative diseases will be discussed.
Disease-Modifying Alzheimer's Disease Therapeutic Candidate
Judith Kelleher-Andersson, PhD, Neuronascent, Inc.
Neuronascent's NNI-362, a new chemical entity, is being developed to treat the cognitive impairment in Alzheimers disease (AD). Alzheimer's Association's statistics indicate nearly 5 million Americans are diagnosed with AD. Age is considered the "greatest risk factor with one in every ten individuals over 65 and nearly half of those over 85 affected". During aging a decrease in hippocampal neuronal progenitor proliferation and survival occurs (i.e. neurogenesis) and in aging AD patients they also have the added progressive neurodegeneration. Interestingly, in early AD the brain appears to compensate for the loss of neurons and attempts to promote neurogenesis, but this proliferation of neuronal progenitors appears ineffectual for repairing and regenerating lost and dysfunctional neurons in the hippocampus. Neuronascent's neurogenic and neuroprotective agent, NNI-362, aims to use the brains own repair and regenerative machinery to reverse the cognitive deficit observed in AD. NNI-362 was administered orally to 19 month aged mice for 6 weeks and compared with aged and young mice receiving only vehicle. This agent reversed the cognitive deficit in aged mice back to young levels, as observed using an object recognition paradigm. A separate model evaluated the ability of NNI-362 to promote neurogenesis and cognitive benefit in Down syndrome (DS) mice (Down syndrome individuals often suffer from AD much earlier) versus DS mice and wild type (WT) mice receiving vehicle alone. NNI-362 administered daily for just three to four weeks was able to retain the number of proliferating neuronal progenitors in the hippocampus equivalent to that seen in wild type mice, while at the same time improving cognition as determined in both a contextual memory and a fear conditioning paradigm over DS mice receiving vehicle. Since Neuronascent's small molecule agent appears to increase the overall number of hippocampal neurons and at the same time improve memory, the results suggest a disease-modifying therapeutic for AD. Further studies with NNI-362 would determine the lowest effective dose in aged and DS mice and obtain all GLP safety information required for an IND submission, to eventually determine if NNI-362 can slow or even reverse the memory deficit in AD patients. JKA founded Neuronascent.
NNI-351, Disease-Modifying Down Syndrome Therapeutic Candidate
NNI-351 is a patented, preclinical-phase therapeutic candidate for Down syndrome (DS). DS is a genetic disorder (trisomy) that causes cognitive impairment in 1/700 live births. Presently, no therapies address the developmental impairment in DS, an impairment that potentially results from reduced neuron formation in key areas of the brain. Dyrk1a, over-expressed in DS, appears to play some role in inhibiting neurogenesis that impairs cognition in developing brain. An inhibitor of Dyrk1a phosphorylation activity, as well as a modulator of other kinases critical to neuron differentiation and maturation, could therefore reverse the reduced neuron numbers in key cognitive areas of the DS brain. NNI-351, was shown to inhibit Dyrk1a activity in a biochemical assay, and induced human neuronal progenitor cell proliferation and differentiation to neurons, while in culture. With no safety concerns by Irwin screen, Ames testing or hERG analysis and no off-target receptor activities, this brain penetrable agent was tested in a Ts65Dn transgenic mouse (Tg) model of DS, to assess long-term behavioral benefit. Tg animals were administered NNI-351 or vehicle and compared to wild type animals for a minimum of three weeks prior to beginning behavioral assessment. Brains were removed following four weeks of daily administration to assess neurogenesis activity. NNI-351 maintained the level of Ki67 labeled dividing neuronal progenitors in the dentate gyrus of DS mice at wild-type levels, even through one-month of administration. This longterm hippocampal neurogenesis correlated with a significant improvement in contextual memory and reduced hyperactivity in Tg mice, where behavioral assessments always occurred 24 hrs post-dosing. Since NNI-351 modifies the brain, by increasing the number of hippocampal neurons, at the same time improving contextual memory over that chronic period, these results suggest a true disease-modifying therapeutic. A GABA-A inverse agonist, entering Phase I clinical studies, aims to only provide symptomatic relief to adults with DS. NNI-351 has also shown long-term benefit in reducing anxiety, enhancing memory and in reducing depressive activity in normal and PTSD mice. With long-term behavioral benefit correlated with cellular brain changes, Neuronascent is planning IND-enabling studies aimed at initiating safety and POC human trials. JKA is founder of Neuronascent.
NeurApheresis for CNS Inflammatory Disorders
Nandan Lad, MD, PhD, Duke University Medical Center Many neuroinflammatory and neurodegenerative conditions are caused by certain neurotoxic factors (inflammatory cells, antibodies, misfolded proteins, microbes such as bacteria/ viruses, etc.) present in cerebrospinal fluid (CSF). These conditions include acute and sub-acute forms of Multiple Sclerosis (MS), Cerebral Vasospasm in the setting of Aneurysmal Subarachnoid Hemorrhage (SAH), Guillain-Barré Syndrome (GBS), Meningitis, etc. Examples of the chronic conditions include MS, Alzheimers (AD) and Parkinsons disease (PD). Presently, limited and poorly effective medical options exist to treat these debilitating, and often devastating neurological conditions. Over the last two decades, several clinical research studies have demonstrated the beneficial effects of directly clearing the deleterious biological factors present in CSF. These studies were performed via intensive, manual CSF removal and filtration steps which are impractical in a routine clinical setting. We have developed an automated CSF processing system (NeurApheresis") as a comprehensive solution for the treatment of specific neuroinflammatory and neurodegenerative conditions. The enabling platform technology has potentially broad applications for diagnosis and therapy of serious brain-related diseases, by purification and treatment of CSF, as well as delivery of therapeutic agents. We summarize our experience from preclinical studies demonstrating proof of principle and feasibility of the platform for removal of cellular material (RBCs). A series of 10 porcine/caprine models were used for demonstrating ease of access using a custom multi-lumen catheter, sizeexclusion filter and smart pump. We found the ability to circulate CSF and create a column of CSF, with selective processing, that allowed for turnover of Liters of fluid over the course of a 8 hour period-equivalent to what the body would take >1 week to accomplish. Potential applications include Neuroinflammatory conditions (SAH, GBS, forms of MS) with targeted drug delivery on the return cycle that bypasses the Blood-brain Barrier (BBB). With recent advances in nanotechnology and ultrafiltration, it is now possible to remove agents on the nanometer scale as opposed to micrometer, nearly a 1000x improvement in targeted filtration than previous systems. With the recent advances in immunotherapy, ex-vivo immunotherapy can target removal of multiple pathogenic molecules from the CSF that directly affect the CNS. Antibodies provide an unprecedented level of specificity to molecules that are too small to remove by present-day size filters. In vivo immunotherapy applications have been met with a number of serious complications including vasogenic edema, microhemorrages and encephalitis. By securing the antibody to an immunoaffinity column, CSF is processed over the antibody cartridge and sequestration of toxic proteins can be achieved with no risk of systemic antibody delivery. The use of biologic separation (for example, Aß and Tau proteins in AD) can be beneficially applied by altering the neuroimmune axis. We are in the process of exploring collaborations and developing an immunoaffinity capture system, for an unprecedented level of specificity. The goal is to leverage the many positive benefits of immunotherapy, while minimizing the side effects of systemic delivery. In addition, it will provide for a multi-pronged approach, based on disease pathophysiology (rather than a single target), and make use of the versatility of a drug-device platform.
Neurofluocytes, a Biophotonics-based Target Engagement Technology for Neurotherapeutics
Quoc Thang Nguyen, PhD, NeurAccel Biosciences Target engagement measures the effectiveness of a compound to act on its intended target (e.g., receptor or ion channel) in vivo, at the preclinical stage. Advances in genetically encoded fluorescent indicators and novel optical imaging modalities now allow creating specific target engagement assays. In this session, I will first present Neurofluocytes, a versatile biophotonics-based target engagement technology for CNS compounds based on implantable fluorescent cellular sensors and functional two-photon microscopy (CNiFERs; Nguyen et al. (2010) Nature Neurosci. 13,127-132). Neurofluocytes are designed to measure the release of virtually any kind of neurotransmitter or neuropeptide in the live brain as well as the activation of their receptors with unprecedented temporal resolution and sensitivity. I will then describe applying Neurofluocytes to validate compounds against schizophrenia and to perform research on epilepsy.
Lu AA21004, A Novel Multimodal Antidepressant
Connie Sanchez, PhD, Lundbeck Research USA Inc.
Introduction: Lu AA21004 is a novel multimodal antidepressant in clinical phase III development. In the proof-ofconcept study it was efficacious and well tolerated in patients with MDD 1 . In vitro it is a 5-HT 3 and 5-HT 7 receptor antagonist, 5-HT 1B receptor partial agonist, 5-HT 1A receptor agonist and inhibitor of the 5-HT transporter (SERT) 2 . Here we investigate the nonclinical effects of Lu AA21004 on target occupancies, neurotransmitter levels in the brain, and responses in behavioral models of relevance for antidepressant activity and cognitive processing in rats. Methods: Occupancies of Lu AA21004 at the 5-HT 3 and 5-HT 1B receptors and the SERT were measured by ex vivo radioligand binding in brain slices, and 5-HT 1A receptor occupancy was measured by in vivo cold competition binding. Effects on extracellular neurotransmitter levels of 5-HT, NE, DA, ACh and HA were measured in the prefrontal cortex by microdialysis. Antidepressant potential, measured in the forced swim test (FST), was assessed after repeated dosing and compared to fluoxetine (10 and 16 mg/kg/day, respectively, po for 16 days) in female rats subjected to multiple progesterone withdrawals. Effects on acquisition and consolidation of contextual memory were studied in the fear conditioning paradigm; episodic memory was evaluated in the novel object recognition test. Results: Lu AA21004 (0.1-10 mg/kg, sc) dose-dependently occupied the studied targets; the in vivo potency ranking was in agreement with the in vitro potencies. Lu AA21004 (2.5-10 mg/kg, s.c.) dose-dependently increased extracellular levels of 5-HT, NE, DA, ACh and HA in the prefrontal cortex. In the progesterone withdrawal model, Lu AA21004 produced an antidepressant-like response in the FST whereas fluoxetine was inactive. These Lu AA21004 and fluoxetine doses produced similar SERT occupancies. Thus, Lu AA21004 exerts its antidepressant-like activity via mechanisms beyond SERT inhibition. Finally, Lu AA21004 enhanced memory of rats in the cognition models (5-10 mg/kg, s.c.). Conclusion: Consistent with its in vitro profile, Lu AA21004 engaged several targets at pharmacologically active doses in vivo. It increased activity of several neurotransmitter systems, showed antidepressant-like effect in a disease-relevant model insensitive to fluoxetine, and enhanced cognitive function in nonclinical models. This multimodal activity may translate into a unique therapeutic profile. 2-deoxy-D-glucose (2DG) differs from glucose only by removal of a single oxygen atom at the 2 position. Like glucose, 2DG undergoes activity-dependent uptake into cells but cannot undergo enzymatic conversion, and thereby reversibly inhibits glycolysis. 2DG has acute actions against seizures evoked by 6 hz and audiogenic stimulation in mice, chronic antiepileptic 'disease-modifying' effects consisting of 2-fold slowing of kindling progression in rats, and is currently in preclinical development for treatment of epilepsy. Therapeutic indications currently under consideration for 2DG in epilepsy include treatment of sporadic seizures, clusters of seizures, status epilepticus, intractable epilepsies, and combination with device and stimulation therapy. With 'disease-modifying'actions against progression of seizures evoked by kindling and previous studies indicating neuroprotective effects of 2DG against ischemic damage, the effects of 2DG were investigated in a rodent model of traumatic brain injury (TBI) to determine if 2DG might have favorable therapeutic effects against structural damage and long-term consequences dependent on lesion-induced plasticity such as post-traumatic epilepsy (PTE) or posttraumatic stress disorder (PTSD). TBI was induced by controlled cortical impact (CCI) in the frontal cortex or dorsal hippocampal region of normal Sprague Dawley rats, and in unique strains of rats bred for susceptibility or resistance to progression of kindled seizures evoked by perforant path stimulation of the hippocampus. Serial in-vivo magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) during a 6 month period following CCI demonstrated progressively increasing ventricle volume, increasing hippocampal diffusion abnormalities, and evolving patterns of hippocampal and corpus callosum anisotropy.
Distinct patterns of structural abnormalities were observed in kindling-susceptible and kindling-resistant rat strains. Brief treatment with 2DG (40 mg/kg at the time of injury and 250 mg/kg/day for 2 weeks) did not modify the severity of the initial injury, but reduced the progression of structural damage assessed by MRI and DTI measures during the 6 month observation period after TBI. 2DG has neuroprotective effects against progression of structural damage after TBI, and studies are underway to evaluate the possibility that treatment with 2DG might also have favorable effects on longterm consequences such as PTE and PTSD. An effective oxygen therapeutic could deliver oxygen to ischemic brain tissue and keep neurons in the penumbra alive, potentially prolonging the therapeutic window for treatment of stroke. An ideal agent would have low toxicity and a good safety profile affording a high therapeutic index. The oxygen therapeutic should not increase oxidative stress and not exacerbate ischemia/reperfusion (IR) injury. In the quest to develop such an agent we studied DDFPe. DDFPe was tested as an ultrasound contrast agent (USCA) in over 2,000 patients and was safe. An embolic stroke model in rabbits was used to study DDFPe. DDFPe was administered as repetitive IV bolus injections every 90 minutes to rabbits at different starting time points post stroke. Animals were killed at 4, 7 or 24 hours post stroke and cerebral volume of infarct was quantified histologically. DDFPe was active at doses of 0.1 mL, 0.3 mL and 0.6 mL/kg, significantly decreasing stroke volume by about 80 -90 % compared to control at all time-points when it was first administered 1 hour post stroke. When it was first administered 6 hours post stroke, it made no difference in animals sacrificed at 7 hours. DDFPe was tested extensively in human subjects as a USCA at doses of 0.1 mL/kg and was tested as high as 0.35 mL/kg (x 2 doses) in volunteers for PK studies. It was safe in bolus IV injection at dose of 1.1 mL/kg in primates. Low dose of DDFPe, safety profile and preclinical efficacy data in stroke model suggest potential efficacy for DDFPe as neuroprotectant for treatment of stroke. Current work is directed to studying effects of DDFPe in I/R injury and longer time-points post stroke with functional recovery.
